A systematic review of the therapeutics for prion diseases

Brain and Nerve

Volumn 61, Issue 8, 2009, Pages 929-938

  Sakaguchi, Suehiro ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

Neurodegeneration; Prion; Prion disease; Prion protein; Therapy

Indexed keywords

PRION PROTEIN;

BLOOD BRAIN BARRIER; CHRONIC WASTING DISEASE; CREUTZFELDT JAKOB DISEASE; DRUG EFFICACY; DRUG MECHANISM; FATAL FAMILIAL INSOMNIA; GERSTMANN STRAUSSLER SCHEINKER SYNDROME; HUMAN; INCUBATION TIME; NONHUMAN; PATHOGENESIS; PRION; PRION DISEASE; REVIEW; SCRAPIE; SURVIVAL TIME; SYSTEMATIC REVIEW;

AMINOPYRIDINES; ANIMALS; ANTIBODIES, MONOCLONAL; BLOOD-BRAIN BARRIER; BRAIN; CATTLE; CLINICAL TRIALS AS TOPIC; DRUG DISCOVERY; GENE SILENCING; HUMANS; PENTOSAN SULFURIC POLYESTER; POLYMERS; PRION DISEASES; PROTEIN ISOFORMS; PRPC PROTEINS; PRPSC PROTEINS; QUINACRINE; SPECIES SPECIFICITY;

EID: 69549126364     PISSN: 18816096     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (57)

1. Prusiner SB: Biology and genetics of prion diseases. Annu Rev Microbiol 48: 655-686, 1994
2. Chatelain J, Cathala F, Brown P, Raharison S, Court L, et al: Epidemiologic comparisons between Creutzfeldt-Jakob disease and scrapie in France during the 12-year period 1968-1979. J Neurol Sci 51: 329-337, 1981
3. Bruce ME, Will RG, Ironside JW, McConnell I, Drummond D, et al: Transmissions to mice indicate that 'new variant' CJD is caused by the BSE agent. Nature 389: 498-501, 1997
4. Hill AF, Desbruslais M, Joiner S, Sidle KC, Gowland I, et al: The same prion strain causes vCJD and BSE. Nature 389: 448-450, 526, 1997 (Pubitemid 27435311)
5. Zou S, Fang CT, Schonberger LB: Transfusion transmission of human prion diseases. Transfus Med Rev 22: 58-69, 2008 (Pubitemid 350184249)
6. Prusiner SB: Prions. Proc Natl Acad Sci U S A 95: 13363-13383, 1998
7. Riek R, Hornemann S, Wider G, Glockshuber R, Wuthrich K: NMR characterization of the full-length recombinant murine prion protein, mPrP (23-231). FEBS Lett 413: 282-288, 1997 (Pubitemid 27353285)
8. Prusiner SB: Molecular biology of prion diseases. Science 252: 1515-1522, 1991
9. Pan KM, Baldwin M, Nguyen J, Gasset M, Serban A, et al: Conversion of alpha-helices into beta-sheets features in the formation of the scrapie prion proteins. Proc Natl Acad Sci U S A 90: 10962-10966, 1993 (Pubitemid 2007975)
10. Prusiner SB: Novel proteinaceous infectious particles cause scrapie. Science 216: 136-144, 1982
11. Prusiner SB: Early evidence that a protease-resistant protein is an active component of the infectious prion. Cell 116: S109, 1 p following S113, 2004
12. Bueler H, Aguzzi A, Sailer A, Greiner RA, Autenried P, et al: Mice devoid of PrP are resistant to scrapie. Cell 73: 1339-1347, 1993 (Pubitemid 23201147)
13. Prusiner SB, Groth D, Serban A, Koehler R, Foster D, et al: Ablation of the prion protein (PrP) gene in mice prevents scrapie and facilitates production of anti-PrP antibodies. Proc Natl Acad Sci U S A 90: 10608-10612, 1993 (Pubitemid 23347091)
14. Sakaguchi S, Katamine S, Shigematsu K, Nakatani A, Moriuchi R, et al: Accumulation of proteinase K-resistant prion protein (PrP) is restricted by the expression level of normal PrP in mice inoculated with a mouse-adapted strain of the Creutzfeldt-Jakob disease agent. J Virol 69: 7586-7592, 1995
15. Manson JC, Clarke AR, McBride PA, McConnell I, Hope J: PrP gene dosage determines the timing but not the final intensity or distribution of lesions in scrapie pathology. Neurodegeneration 3: 331-340, 1994
16. Castilla J, Saa P, Hetz C, Soto C: In vitro generation of infectious scrapie prions. Cell 121: 195-206, 2005
17. Cohen FE, Pan KM, Huang Z, Baldwin M, Fletterick RJ, et al: Structural clues to prion replication. Science 264: 530-531, 1994
18. Lansbury PT: Mechanism of scrapie replication. Science 265: 1510, 1994
19. Silveira JR, Raymond GJ, Hughson AG, Race RE, Sim VL, et al: The most infectious prion protein particles. Nature 437: 257-261, 2005
20. DeArmond SJ, Prusiner SB: Etiology and pathogenesis of prion diseases. Am J Pathol 146: 785-811, 1995
21. Pattison IH: Scrapie in the welsh mountain breed of sheep and its experimental transmission to goats. Vet Rec 77: 1388-1390, 1965
22. Williams ES: Chronic wasting disease. Vet Pathol 42: 530-549, 2005
23. Campana V, Sarnataro D, Zurzolo C: The highways and byways of prion protein trafficking. Trends Cell Biol 15: 102-111, 2005 (Pubitemid 40188220)
24. Leucht C, Simoneau S, Rey C, Vana K, Rieger R, et al: The 37 kDa/67 kDa laminin receptor is required for PrP (Sc) propagation in scrapie-infected neuronal cells. EMBO Rep 4: 290-295, 2003 (Pubitemid 36511726)
25. Trevitt CR, Collinge J: A systematic review of prion therapeutics in experimental models. Brain 129: 2241-2265, 2006
26. Sakaguchi S: Recent developments in therapeutics for prion diseases. Expert Opin Ther Patents 18: 35-59, 2008
27. Mallucci G, Dickinson A, Linehan J, Klohn PC, Brandner S, et al: Depleting neuronal PrP in prion infection prevents disease and reverses spongiosis. Science 302: 871-874, 2003 (Pubitemid 37339628)
28. Daude N, Marella M, Chabry J: Specific inhibition of pathological prion protein accumulation by small interfering RNAs. J Cell Sci 116: 2775-2779, 2003 (Pubitemid 36857228)
29. Pfeifer A, Eigenbrod S, Al-Khadra S, Hofmann A, Mitteregger G, et al: Lentivector-mediated RNAi efficiently suppresses prion protein and prolongs survival of scrapie-infected mice. J Clin Invest 116: 3204-3210, 2006 (Pubitemid 44878634)
30. Sakaguchi S: Molecular biology of prion protein and its first homologous protein. J Med Invest 54: 211-223, 2007 (Pubitemid 350143734)
31. Peretz D, Williamson RA, Kaneko K, Vergara J, Leclerc E, et al: Antibodies inhibit prion propagation and clear cell cultures of prion infectivity. Nature 412: 739-743, 2001 (Pubitemid 32771997)
32. Enari M, Flechsig E, Weissmann C: Scrapie prion protein accumulation by scrapie-infected neuroblastoma cells abrogated by exposure to a prion protein antibody. Proc Natl Acad Sci U S A 98: 9295-9299, 2001 (Pubitemid 32743910)
33. Kim CL, Karino A, Ishiguro N, Shinagawa M, Sato M, et al: Cell-surface retention of PrPC by anti-PrP antibody prevents protease-resistant PrP formation. J Gen Virol 85: 3473-3482, 2004 (Pubitemid 39445468)
34. Perrier V, Solassol J, Crozet C, Frobert Y, MourtonGilles C, et al: Anti-PrP antibodies block PrPSc replication in prion-infected cell cultures by accelerating PrPC degradation. J Neurochem 89: 454-463, 2004 (Pubitemid 38495993)
35. Song CH, Furuoka H, Kim CL, Ogino M, Suzuki A, et al: Effect of intraventricular infusion of anti-prion protein monoclonal antibodies on disease progression in prion-infected mice. J Gen Virol 89: 1533-1544, 2008
36. Lefebvre-Roque M, Kremmer E, Gilch S, Zou WQ, Feraudet C, et al: Toxic effects of intracerebral PrP antibody administration during the course of BSE infection in mice. Prion 1: 198-206, 2007
37. Solforosi L, Criado JR, McGavern DB, Wirz S, Sanchez-Alavez M, et al: Cross-linking cellular prion protein triggers neuronal apoptosis in vivo. Science 303: 1514-1516, 2004 (Pubitemid 38314420)
38. Meier P, Genoud N, Prinz M, Maissen M, Rulicke T, et al: Soluble dimeric prion protein binds PrP (Sc) in vivo and antagonizes prion disease. Cell 113: 49-60, 2003 (Pubitemid 36411959)
39. Genoud N, Ott D, Braun N, Prinz M, Schwarz P, et al: Antiprion prophylaxis by gene transfer of a soluble prion antagonist. Am J Pathol 172: 1287-1296, 2008 (Pubitemid 351671541)
40. Kimberlin RH, Walker CA: The antiviral compound HPA-23 can prevent scrapie when administered at the time of infection. Arch Virol 78: 9-18, 1983
41. Gilch S, Winklhofer KF, Groschup MH, Nunziante M, Lucassen R, et al: Intracellular re-routing of prion protein prevents propagation of PrP (Sc) and delays onset of prion disease. EMBO J 20: 3957-3966, 2001 (Pubitemid 32751812)
42. Supattapone S, Wille H, Uyechi L, Safar J, Tremblay P, et al: Branched polyamines cure prion-infected neuroblastoma cells. J Virol 75: 3453-3461, 2001 (Pubitemid 32225908)
43. Caughey B, Race RE: Potent inhibition of scrapie-associated PrP accumulation by Congo red. J Neurochem 59: 768-771, 1992
44. Caspi S, Halimi M, Yanai A, Sasson SB, Taraboulos A, et al: The anti-prion activity of Congo red. Putative mechanism. J Biol Chem 273: 3484-3489, 1998 (Pubitemid 28109769)
45. Ishikawa K, Kudo Y, Nishida N, Suemoto T, Sawada T, et al: Styrylbenzoazole derivatives for imaging of prion plaques and treatment of transmissible spongiform encephalopathies. J Neurochem 99: 198-205, 2006 (Pubitemid 44395142)
46. Kawasaki Y, Kawagoe K, Chen CJ, Teruya K, Sakasegawa Y, et al: Orally administered amyloidophilic compound is effective in prolonging the incubation periods of animals cerebrally infected with prion diseases in a prion strain-dependent manner. J Virol 81: 12889-12898, 2007 (Pubitemid 350156926)
47. Forloni G, Iussich S, Awan T, Colombo L, Angeretti N, et al: Tetracyclines affect prion infectivity. Proc Natl Acad Sci U S A 99: 10849-10854, 2002
48. Caughey WS, Raymond LD, Horiuchi M, Caughey B: Inhibition of protease-resistant prion protein formation by porphyrins and phthalocyanines. Proc Natl Acad Sci U S A 95: 12117-12122, 1998 (Pubitemid 28483728)
49. Ertmer A, Gilch S, Yun SW, Flechsig E, Klebl B, et al: The tyrosine kinase inhibitor STI571 induces cellular clearance of PrPSc in prion-infected cells. J Biol Chem 279: 41918-41927, 2004 (Pubitemid 39313641)
50. Nordstrom EK, Luhr KM, Ibanez C, Kristensson K: Inhibitors of the mitogen-activated protein kinase kinase 1/2 signaling pathway clear prion-infected cells from PrPSc. J Neurosci 25: 8451-8456, 2005 (Pubitemid 41324731)
51. Kuwata K, Nishida N, Matsumoto T, Kamatari YO, Hosokawa-Muto J, et al: Hot spots in prion protein for pathogenic conversion. Proc Natl Acad Sci U S A 104: 11921-11926, 2007 (Pubitemid 47185606)
52. Doh-ura K, Ishikawa K, Murakami-Kubo I, Sasaki K, Mohri S, et al: Treatment of transmissible spongiform encephalopathy by intraventricular drug infusion in animal models. J Virol 78: 4999-5006, 2004 (Pubitemid 38581450)
53. Rainov NG, Tsuboi Y, Krolak-Salmon P, Vighetto A, Doh-Ura K: Experimental treatments for human transmissible spongiform encephalopathies: is there a role for pentosan polysulfate? Expert Opin Biol Ther 7: 713-726, 2007
54. Nakajima M, Yamada T, Kusuhara T, Furukawa H, Takahashi, M et al: Results of quinacrine administration to patients with Creutzfeldt-Jakob disease. Dement Geriatr Cogn Disord 17: 158-163, 2004 (Pubitemid 38339741)
55. Dhar S, Bitting RL, Rylova SN, Jansen PJ, Lockhart E, et al: Flupirtine blocks apoptosis in batten patient lymphoblasts and in human postmitotic CLN3- and CLN2-deficient neurons. Ann Neurol 51: 448-466, 2002 (Pubitemid 34260775)
56. Perovic S, Schroder HC, Pergande G, Ushijima H, Muller WE: Effect of flupirtine on Bcl-2 and glutathione level in neuronal cells treated in vitro with the prion protein fragment (PrP106-126). Exp Neurol 147: 518-524, 1997 (Pubitemid 27497313)
57. Otto M, Cepek L, Ratzka P, Doehlinger S, Boekhoff I, et al: Efficacy of flupirtine on cognitive function in patients with CJD: A double-blind study. Neurology 62: 714-718, 2004 (Pubitemid 38298945)